miR-429 Identified by Dynamic Transcriptome Analysis Is a New Candidate Biomarker for Colorectal Cancer Prognosis
miR-429 Identified by Dynamic Transcriptome Analysis Is a New Candidate Biomarker for Colorectal Cancer Prognosis
复制标题
动态转录组分析鉴定出 miR-429 是结直肠癌预后的新候选生物标志物
DOI：
10.1089/omi.2012.0132
复制
发表时间：
2014-01-01
影响因子：
3.3
通讯作者：
Li, Xiayu
中科院分区：
文献类型：
--
作者：
Sun, Yingnan;Shen, Shourong;Li, Xiayu
结直肠癌（Colorectal cancer，CRC）是一种常见的胃肠道恶性肿瘤。在过去的十年中，预防性和个性化医学的努力得到了加强，并注意到新形式的生物标志物。在本研究中，microRNA和遗传分析同时进行，以在有或无淋巴结或远处转移的原发性肿瘤之间进行差异转录组分析。系列测试聚类（STC）分析表明，20个基因和两个microRNA显示出与肿瘤，淋巴结和转移（TNM）阶段相关的独特表达模式。通过GO和Pathway分析对所选靶基因进行了表征。microRNA-靶基因网络分析显示，miR-429位于网络的中心，表明miR-429可能在CRC的发展中起重要作用。实时荧光定量PCR和组织芯片检测结果显示，miR-429在结直肠癌进展阶段呈动态表达，在II期和III期临床进展阶段表达显著下调。miR-429的低表达与结直肠癌预后不良相关。总之，miR-429作为CRC预后的候选生物标志物值得进一步的临床翻译研究。还需要识别其他下游靶点和伴随的基因功能，以设计一个合理的关键路径，为易患CRC或被诊断患有CRC的人提供个性化药物。
Colorectal cancer (CRC) is a common malignant gastrointestinal cancer. Efforts for preventive and personalized medicine have intensified in the last decade with attention to novel forms of biomarkers. In the present study, microRNA and genetic analyses were performed in tandem for differential transcriptome profiling between primary tumors with or without nodes or distant metastases. Serial Test Cluster (STC) analysis demonstrated that 20 genes and two microRNAs showed distinctive expression patterns associated with the tumor, node, and metastasis (TNM) stage. The selected target genes were characterized by GO and Pathway analysis. A microRNA-target gene network analysis showed that miR-429 resided in the center of the network, indicating that miR-429 might serve important roles in the development of CRC. Real-time PCR and tissue microarrays showed that miR-429 had a dynamic expression pattern during the CRC progression stage, and was significantly downregulated in stage II and stage III clinical progression. The low expression of miR-429 was correlated with poor prognosis for CRC. Taken together, miR-429 warrant further clinical translation research as a candidate biomarker for CRC prognosis. Additional downstream targets and attendant gene function also need to be discerned to design a sound critical path to personalized medicine for persons susceptible to, or diagnosed with CRC.